The way to view BC is widely and constantly changing, mostly after the further characterization of its molecular hallmarks that includes, for instance, the immunohistochemical markers ER, PR, HER2; the genomic markers BRCA1, BRCA2, and PIK3CA; and immunomarkers such as PD-L1. This evidence concerns the gene BRCA2 and breast cancer.